This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2022 Aug 11;387(6):558-561.

doi: 10.1056/NEJMe2209692.

T-Cell Engagers - Modern Immune-Based Therapies for Multiple Myeloma

Sham Mailankody¹, Ola Landgren¹

Affiliations

Affiliation

¹ From the Myeloma and Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (S.M.); and the Division of Myeloma, Sylvester Comprehensive Cancer Center, University of Miami, Miami (O.L.).

PMID: 35947712
DOI: 10.1056/NEJMe2209692

Editorial

T-Cell Engagers - Modern Immune-Based Therapies for Multiple Myeloma

Sham Mailankody et al. N Engl J Med. 2022.

. 2022 Aug 11;387(6):558-561.

doi: 10.1056/NEJMe2209692.

Authors

Sham Mailankody¹, Ola Landgren¹

Affiliation

¹ From the Myeloma and Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (S.M.); and the Division of Myeloma, Sylvester Comprehensive Cancer Center, University of Miami, Miami (O.L.).

PMID: 35947712
DOI: 10.1056/NEJMe2209692

No abstract available

PubMed Disclaimer

Comment on

Teclistamab in Relapsed or Refractory Multiple Myeloma.
Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Nooka AK, Martin T, Rosinol L, Chari A, Karlin L, Benboubker L, Mateos MV, Bahlis N, Popat R, Besemer B, Martínez-López J, Sidana S, Delforge M, Pei L, Trancucci D, Verona R, Girgis S, Lin SXW, Olyslager Y, Jaffe M, Uhlar C, Stephenson T, Van Rampelbergh R, Banerjee A, Goldberg JD, Kobos R, Krishnan A, Usmani SZ. Moreau P, et al. N Engl J Med. 2022 Aug 11;387(6):495-505. doi: 10.1056/NEJMoa2203478. Epub 2022 Jun 5. N Engl J Med. 2022. PMID: 35661166 Free PMC article. Clinical Trial.

Similar articles

The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies.
Hoyos V, Borrello I. Hoyos V, et al. Blood. 2016 Sep 29;128(13):1679-87. doi: 10.1182/blood-2016-05-636357. Epub 2016 Aug 9. Blood. 2016. PMID: 27506540 Review.
Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF, Anderson KC, Tai YT. Cho SF, et al. Front Immunol. 2018 Aug 10;9:1821. doi: 10.3389/fimmu.2018.01821. eCollection 2018. Front Immunol. 2018. PMID: 30147690 Free PMC article. Review.
Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C. Chung C. Pharmacotherapy. 2017 Jan;37(1):129-143. doi: 10.1002/phar.1871. Epub 2017 Jan 6. Pharmacotherapy. 2017. PMID: 27870103 Review.
Advances in immunotherapy in multiple myeloma.
Boussi L, Niesvizky R. Boussi L, et al. Curr Opin Oncol. 2017 Nov;29(6):460-466. doi: 10.1097/CCO.0000000000000407. Curr Opin Oncol. 2017. PMID: 28877078 Review.
Role of Immune Therapies for Myeloma.
Rosenblatt J, Avigan D. Rosenblatt J, et al. J Natl Compr Canc Netw. 2015 Nov;13(11):1440-7. doi: 10.6004/jnccn.2015.0168. J Natl Compr Canc Netw. 2015. PMID: 26553769 Review.

See all similar articles

Cited by

GPRC5D as a novel immunotherapeutic target in multiple myeloma.
Nath K, Costa BA, Mailankody S. Nath K, et al. Nat Rev Clin Oncol. 2023 May;20(5):281-282. doi: 10.1038/s41571-023-00735-4. Nat Rev Clin Oncol. 2023. PMID: 36725915 No abstract available.
Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin.
Caracciolo D, Juli G, Riillo C, Coricello A, Vasile F, Pollastri S, Rocca R, Scionti F, Polerà N, Grillone K, Arbitrio M, Staropoli N, Caparello B, Britti D, Loprete G, Costa G, Di Martino MT, Alcaro S, Tagliaferri P, Tassone P. Caracciolo D, et al. J Transl Med. 2022 Oct 22;20(1):482. doi: 10.1186/s12967-022-03705-z. J Transl Med. 2022. PMID: 36273153 Free PMC article.
Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results.
Mailankody S, Matous JV, Chhabra S, Liedtke M, Sidana S, Oluwole OO, Malik S, Nath R, Anwer F, Cruz JC, Htut M, Karski EE, Lovelace W, Dillon M, Butz E, Ying W, Balakumaran A, Kumar SK. Mailankody S, et al. Nat Med. 2023 Feb;29(2):422-429. doi: 10.1038/s41591-022-02182-7. Epub 2023 Jan 23. Nat Med. 2023. PMID: 36690811 Clinical Trial.
New horizons in our understanding of precursor multiple myeloma and early interception.
Cordas Dos Santos DM, Toenges R, Bertamini L, Alberge JB, Ghobrial IM. Cordas Dos Santos DM, et al. Nat Rev Cancer. 2024 Dec;24(12):867-886. doi: 10.1038/s41568-024-00755-x. Epub 2024 Oct 16. Nat Rev Cancer. 2024. PMID: 39414947 Review.
Targeting GPRC5D for multiple myeloma therapy.
Zhou D, Wang Y, Chen C, Li Z, Xu K, Zhao K. Zhou D, et al. J Hematol Oncol. 2024 Sep 28;17(1):88. doi: 10.1186/s13045-024-01611-z. J Hematol Oncol. 2024. PMID: 39342286 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information